It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Here we studied HLA blocks and haplotypes in a group of 218 Lacandon Maya Native American using a high-resolution next generation sequencing (NGS) method. We assessed the genetic diversity of HLA class I and class II in this population, and determined the most probable ancestry of Lacandon Maya HLA class I and class II haplotypes. Importantly, this Native American group showed a high degree of both HLA homozygosity and linkage disequilibrium across the HLA region and also lower class II HLA allelic diversity than most previously reported populations (including other Native American groups). Distinctive alleles present in the Lacandon population include HLA-A*24:14 and HLA-B*40:08. Furthermore, in Lacandons we observed a high frequency of haplotypes containing the allele HLA-DRB1*04:11, a relatively frequent allele in comparison with other neighboring indigenous groups. The specific demographic history of the Lacandon population including inbreeding, as well as pathogen selection, may have elevated the frequencies of a small number of HLA class II alleles and DNA blocks. To assess the possible role of different selective pressures in determining Native American HLA diversity, we evaluated the relationship between genetic diversity at HLA-A, HLA-B and HLA-DRB1 and pathogen richness for a global dataset and for Native American populations alone. In keeping with previous studies of such relationships we included distance from Africa as a covariate. After correction for multiple comparisons we did not find any significant relationship between pathogen diversity and HLA genetic diversity (as measured by polymorphism information content) in either our global dataset or the Native American subset of the dataset. We found the expected negative relationship between genetic diversity and distance from Africa in the global dataset, but no relationship between HLA genetic diversity and distance from Africa when Native American populations were considered alone.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Department of Archaeogenetics, Max Planck Institute for the Science of Human History (MPI-SHH), Jena, Germany (GRID:grid.469873.7) (ISNI:0000 0004 4914 1197); Laboratory of Molecular Genetics, Escuela Nacional de Antropología e Historia (ENAH), Mexico City, Mexico (GRID:grid.462439.e) (ISNI:0000 0001 2169 9197)
2 Department of Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Mexico City, Mexico (GRID:grid.419179.3) (ISNI:0000 0000 8515 3604); Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico (GRID:grid.419886.a) (ISNI:0000 0001 2203 4701)
3 Clinical Laboratory of Neurodegenerative Diseases, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”, Mexico City, Mexico (GRID:grid.419204.a) (ISNI:0000 0000 8637 5954)
4 University of Warwick, School of Life Sciences, Coventry, United Kingdom (GRID:grid.7372.1) (ISNI:0000 0000 8809 1613)
5 Laboratory of Molecular Genetics, Escuela Nacional de Antropología e Historia (ENAH), Mexico City, Mexico (GRID:grid.462439.e) (ISNI:0000 0001 2169 9197); Immunogenetics Unit, Técnicas Genéticas Aplicadas a la Clínica (TGAC), Mexico City, Mexico (GRID:grid.462439.e)
6 Department of Transplantation, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMSZ), Mexico City, Mexico (GRID:grid.416850.e) (ISNI:0000 0001 0698 4037)
7 Public Health State Laboratory for Chiapas, Tuxtla Gutierrez, Chiapas, Mexico (GRID:grid.416850.e)
8 Histocompatibility, Immunogenetics and Disease Profiling Laboratory, Stanford Blood Center, Palo Alto, USA (GRID:grid.416850.e); Biology Department, University of Crete, Heraklion, Greece (GRID:grid.8127.c) (ISNI:0000 0004 0576 3437)
9 Department of Neurogenetics and Molecular Biology, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”, Mexico City, Mexico (GRID:grid.419204.a) (ISNI:0000 0000 8637 5954)
10 Histocompatibility, Immunogenetics and Disease Profiling Laboratory, Stanford Blood Center, Palo Alto, USA (GRID:grid.419204.a); Department of Pathology, Stanford University, USA (GRID:grid.419204.a)
11 Clinical Analysis Laboratory, Unidad Médica Familiar (UMF) No. 23, Instituto Mexicano del Seguro Social (IMSS), Tuxtla Gutiérrez, Mexico (GRID:grid.419157.f) (ISNI:0000 0001 1091 9430)
12 Stanford Genome Technology Center, Palo Alto, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
13 Department of Cancer Immunology and Virology, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA (GRID:grid.168010.e)
14 Department of Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Mexico City, Mexico (GRID:grid.419179.3) (ISNI:0000 0000 8515 3604)
15 The William Harvey Research Institute, Barts and London School of Medicine, Queen Mary University of London, London, United Kingdom (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)
16 Department of Pathology, Stanford University, USA (GRID:grid.416850.e)
17 Department of Cancer Immunology and Virology, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA (GRID:grid.416850.e)